Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
PaperCitations, authors & open-access status
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 80 citations, 2017 year and hybrid oa status.
80
Citations
2017
Year
hybrid
OA Status